


**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S)' INFORMATION DISCLOSURE
STATEMENT**

(Use several sheets if necessary)



21327-701CIP

INVENTOR: Gill et al

FILING DATE
January 19, 2000

GROUP ART UNIT 1635

RECEIVED
FEB 21 2001
TECH CENTER 1600/2900

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAM'R INITIAL		DOCUMENT NUMBER	DATE	NAME	Class	Subclass	Filing Date If Appropriate
5/16/02	A1	5,710,136	January 20, 1998	Robinson et al.			
	A2	5,591,721	January 7, 1997	Agrawal et al.			
	A3	5,652,356	July 29, 1997	Agrawal			
	A4	5,641,756	June 24, 1997	Robinson			
	A5	5,639,736	June 17, 1997	Robinson			
	A6	5,639,872	June 17, 1997	Robinson			
	A7	5,661,135	August 26, 1997	Robinson			
	A8	5,264,423	November 23, 1993	Cohen et al.			
	A9	5,652,355	July 29, 1997	Meteliev et al.			

FOREIGN PATENT DOCUMENTS

EXAM'R INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	Subclass	TRANSLAT'N
							yes no
	B1						
	B2						

OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.)

5	C1	Agrawal, S. et al. "Mixed-Backbone Oligonucleotides As Second Generation Antisense Oligonucleotides: <i>In Vitro</i> and <i>In Vivo</i> Studies," (1997) <i>Proc Natl Acad Sci U S A</i> 94, 2620-5.
8	C2	Aguayo, A. et al., "Cellular "Vascular Endothelial Growth Factor Is A Predictor of Outcome In Patients With Acute Myeloid Leukemia" (1999) <i>Blood</i> 94, 3717-21
9	C3	Barleon, B. et al., "Migration of Human Monocytes in Response to Vascular Endothelial Growth Factor (VEGF) Is Mediated Via the VEGF Receptor flt-1," (1996) <i>Blood</i> 87, 3336-43
2	C4	Benjamin, L. E. & Keshet, E. "Conditional Switching of Vascular Endothelial Growth Factor (VEGF) Expression In Tumors: Induction of Endothelial Cell Shedding and Regression of Hemangioblastoma-Like Vessels by VEGF Withdrawal", (1997) <i>Proc Natl Acad Sci U S A</i> 94, 8761-6
7	C5	Benjamin, L. E. et al., "Selective Ablation of Immature Blood Vessels in Established Human Tumors Follows Vascular Endothelial Growth Factor Withdrawal" (1999) <i>J Clin Invest</i> 103, 159-65
4	C6	Chan, A. S. et al., "Expression of Vascular Endothelial Growth Factor and Its Receptors in the Anaplastic Progression of Astrocytoma, Oligodendroglioma, and Ependymoma", (1998) <i>Am J Surg Pathol</i> 22, 816-26


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S)' INFORMATION DISCLOSURE
STATEMENT**

(Use several sheets if necessary)



INVENTOR: Parkash Gill et al.

FILING DATE: 1/19/00

GROUP ART UNIT
1635

RECEIVED
FEB 21 2001
TECH CENTER 1600/2900

M	C7	Charnock-Jones, D. S. et al., "Vascular Endothelial Growth Factor Receptor Localization and Activation in Human Trophoblast and Choriocarcinoma Cells" (1994) <i>Biol Reprod</i> 51, 524-30
M	C8	Clauss, M. et al., "The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities", (1996) <i>J Biol Chem</i> 271, 17629-34
M	C9	Crew, J.P. et al., "Vascular Endothelial Growth Factor Is a Predictor of Relapse and Stage Progression in Superficial Bladder Cancer", (1997) <i>Cancer Res</i> 57, 5281-5
M	C10	De Vries, C. et al., "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor", (1992) <i>Science</i> 255, 989-91
M	C11	Dias, S. et al., "Expression of VEGF And Its Receptor VEGFR-2 By Human Leukemia Cells Generates an Autocrine Loop that Mediates Cell Growth and Migration", (2000) in <i>Proc American Assoc Cancer Res</i> , 41: 792
M	C12	Dvorak, H. F. et al., "Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis", (1995) <i>Am J Pathol</i> 146, 1029-39
M	C13	El-Assal, O. N. et al., "Clinical Significance of Microvessel Density and Vascular Endothelial Growth Factor Expression in Hepatocellular Carcinoma and Surrounding Liver: Possible Involvement of Vascular Endothelial Growth Factor in the Angiogenesis of Cirrhotic Liver (1998) <i>Hepatology</i> 27, 1554-62
M	C14	Ferrara et al., "Purification and Cloning of Vascular Endothelial Growth Factor Secreted by Pituitary Folliculostellate Cells" (1991) <i>Methods Enzymol</i> 198:391-405
M	C15	Fidler, I. J. & Ellis, L. M. "The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis", (1994) <i>Cell</i> 79, 185-8
M	C16	Fine, B. A. et al., "VEGF, flt-1, and KDR/flk-1 as Prognostic Indicators in Endometrial Carcinoma" (2000) <i>Gynecol Oncol</i> 76, 33-9
M	C17	Fong, T. A. et al., "SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types", (1999) <i>Cancer Res</i> 59, 99-106

EXAMINER

DATE CONSIDERED 5/16/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S)' INFORMATION DISCLOSURE
STATEMENT**

(Use several sheets if necessary)

ATTY. DOCKET NO.

21327-701CIP

SERIAL NO.

09/487,023

INVENTOR: Parkash Gill et al.

FILING DATE: 1/19/00

GROUP ART UNIT
1635

RECEIVED
FEB 21 2001

TECH CENTER 1600/2900

K	C18	Herold-Mende, C. et al., "Expression and Functional Significance of Vascular Endothelial Growth Factor Receptors in Human Tumor Cells", (1999) <i>Lab Invest</i> 79, 1573-82
AS	C19	Hida, Y. et al., "Vascular Endothelial Growth Factor Expression is an Independent Negative Predictor in Extrahepatic Biliary Tract Carcinomas", (1999) <i>Anticancer Res</i> 19, 2257-60
AS	C20	Itakura, J. et al., "Concomitant Over-Expression of Vascular Endothelial Growth Factor and Its Receptors in Pancreatic Cancer", (2000) <i>Int J Cancer</i> 85, 27-34
AS	C21	Leung DW et al., "Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen" (1989) <i>Science</i> 246:1306-1309.
AS	C22	Leung, S. Y. et al., "Expression of Vascular Endothelial Growth Factor and its Receptors in Pilocytic Astrocytoma", (1997) <i>Am J Surg Pathol</i> 21, 941-50
AS	C23	Li, X. M. et al., "Significance of Vascular Endothelial Growth Factor mRNA Expression in Invasion and Metastasis of Hepatocellular Carcinoma", (1998) <i>J Exp Clin Cancer Res</i> 17, 13-7
AS	C24	Liu, B. et al., "Melanoma Cell Lines Express VEGF Receptor KDR and Respond to Exogenously Added VEGF", (1995) <i>Biochem Biophys Res Commun</i> 217, 721-7
AS	C25	Linderholm, B. et al., "p53 And Vascular-Endothelial-Growth-Factor (VEGF) Expression Predicts Outcome in 833 Patients With Primary Breast Carcinoma", (2000) <i>Int J Cancer</i> 89, 51-62
AS	C26	Maeda, K. et al., "Prognostic Value of Vascular Endothelial Growth Factor Expression in Gastric Carcinoma", (1996) <i>Cancer</i> 77, 858-63
AS	C27	Maeda, K. et al., "Vascular Endothelial Growth Factor Expression in Preoperative Biopsy Specimens Correlates with Disease Recurrence in Patients with Early Gastric Carcinoma", (1999) <i>Cancer</i> 86, 566-71
AS	C28	Masood R et al (1997) "Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma." <i>Proc. Natl. Acad. Sci. USA</i> 94:979-84
AS	C29	Moriyama, M. et al., "Immunohistochemical Study of Tumour Angiogenesis in Oral Squamous Cell Carcinoma", (1997) <i>Oral Oncol</i> 33, 369-74

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S)' INFORMATION DISCLOSURE
STATEMENT**

(Use several sheets if necessary)



ATTY. DOCKET NO.

21327-701CIP

SERIAL NO.

09/487,023

INVENTOR: Parkash Gill et al.

FILING DATE: 1/19/00

GROUP ART UNIT
1635

RECEIVED
FEB 2 1 2001
TECH CENTER 1600/2900

C30	Paradis, V. et al., "Expression of Vascular Endothelial Growth Factor in Renal Cell Carcinomas", (2000) <i>Virchows Arch</i> 436, 351-6
C31	Plate, K. H. "Control of Tumor Growth Via Inhibition of Tumor Angiogenesis", (1998) <i>Adv Exp Med Biol</i> 451, 57-61
C32	Senger, D. R., et al., "Vascular Permeability Factor (VPF, VEGF) in Tumor Biology" (1993) <i>Cancer Metastasis Rev</i> 12, 303-24
C33	Smith, B. D. et al., "Prognostic Significance of Vascular Endothelial Growth Factor Protein Levels in Oral and Oropharyngeal Squamous Cell Carcinoma" (2000) <i>J Clin Oncol</i> 18, 2046-52
C34	Soker, S. et al., "Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor", (1998) <i>Cell</i> 92, 735-45
C35	Takahashi, T. & Shibuya, M. "The 230 kDa Mature Form of KDR/Flk-1 (VEGF Receptor-2) Activates the PLC- γ Pathway and Partially Induces Mitotic Signals in NIH3T3 Fibroblasts", (1997) <i>Oncogene</i> 14, 2079-89
C36	Terman, B. I. et al., "Identification of the KDR Tyrosine Kinase as a Receptor For Vascular Endothelial Cell Growth Factor", (1992) <i>Biochem Biophys Res Commun</i> 187, 1579-86
C37	Tischer et al "The Human Gene for Vascular Endothelial Growth Factor", (1991) <i>J. Biol Chem</i> 266:11947-540
C38	Waltenberger, J. et al., "Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor", (1994) <i>J Biol Chem</i> 269, 26988-95
C39	Wang, D. et al., "Homeostatic Modulation of Cell Surface KDR and Flt1 Expression and Expression of the Vascular Endothelial Cell Growth Factor (VEGF) Receptor mRNAs by VEGF", (2000) <i>J Biol Chem</i> 275, 15905-15911
C40	Yamamoto S. et al., "Expression of Vascular Endothelial Growth Factor (VEGF) in Epithelial Ovarian Neoplasms: Correlation With Clinicopathology and Patient Survival, and Analysis of Serum VEGF Levels", (1997) <i>Br J Cancer</i> , 76(9): 1221-7

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S)' INFORMATION DISCLOSURE
STATEMENT**


(Use several sheets if necessary)

ATTY. DOCKET NO.
21327-701CIPSERIAL NO.
09/487,023

INVENTOR: Parkash Gill et al.

FILING DATE: 1/19/00

GROUP ART UNIT
1635**RECEIVED**
FEB 21 2001
TECH CENTER 1620/2900

	C41	Yukita, A. et al., "Suppression of Ascites Formation and Re-Accumulation Associated With Human Ovarian Cancer by an Anti-VPF Monoclonal Antibody in Vivo", (2000) <i>Anticancer Res</i> 20, 155-60
---	-----	--

EXAMINER

DATE CONSIDERED

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).